Moderate Intensity Training in Patients With Truncating Genetic Variants in TTN.
NCT ID: NCT05180188
Last Updated: 2022-11-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
14 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-02-14
Study Completion Date
2022-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim is to investigate the effect of an 8-week moderate-intensity exercise program on aerobic fitness and cardiac contractility in patients with truncations of the sarcomeric protein titin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Skeletal Muscle and Adipose Tissue Responses After Acute Exercise: Comparing Effects of Three Different Intensities
NCT05365334
Cellular Responses Within Skeletal Muscle in Response to Exercise of Different Intensities
Relationship Between the Cellular Responses in Skeletal Muscle and the Changes in the Metabolomic Profile
Changes Within Adipose Tissue in Response to Exercise at the Three Different Intensities
COMPLETED
NA
Gene - Exercise Research Study
NCT00976742
Cardiovascular Disease Risk Factors
COMPLETED
NA
Exercise-induced Changes in DNA-methylation
NCT01931072
Healthy
TERMINATED
NA
A Study of High-intensity Strength Training and Thoracic Aorta Dilatation
NCT06684496
Thoracic Aorta Dilatation
RECRUITING
Effects of High-intensity Interval Training on Myocardial Strain in Metabolic Syndrome Patients
NCT06262256
High-Intensity Interval Training
Metabolic Syndrome
Myocardial Dysfunction
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mutations leading to truncations of the large sarcomeric protein titin was discovered in 2012 as the most prevalent genetic cause of familial dilated cardiomyopathy, affecting approximately 25% of all cases of familial dilated cardiomyopathy. The dilated cardiomyopathy phenotype associated with truncating titin variants (TTNtv) is associated with a high prevalence of arrhythmias but is generally thought to represent a relatively mild DCM phenotype, which often responds well to medical therapy.
In vitro experiments on human induced pluripotent stem cells show that TTNtv leads to sarcomere insufficiency, impaired responses to mechanical and β-adrenergic stress, and attenuated growth factor and cell signaling activation. Experiments in animal models suggest patients with TTNtv are intolerant to long-lasting hemodynamic stress. This finding is supported by clinical studies in which a significant proportion of patients with peripartum cardiomyopathy, alcoholic cardiomyopathy and chemotherapy-induced cardiomyopathy were found to carry TTNtv.
So far, no interventional studies have been carried out specifically in patients with TTNtv. In an older study putative variants in TTN have been suggested to be associated with cardiac adaptations to endurance training, namely the rate of change in stroke volume during submaximal exercise.
Previous interventional exercise-studies in patients with a range of mutations in genes encoding proteins of the cytoskeleton, sarcomere, ion-channels and enzymes of the mitochondrial respiratory chain, safely improves oxidative fitness. Studies carried out on patients with heart failure of mixed etiologies and in patients with hypertrophic cardiomyopathy reveals similar beneficial effects of exercise. These studies reject the idea that training "diseased" muscle tissue leads to further muscle damage or is ineffective.
Many patients with cardiomyopathy often lead a sedentary life but aspire to live a physically active lifestyle and take advantage of the many documented health benefits of exercise. However, recommendations for engaging in physical activity in patients with heart failure and cardiomyopathies are vague since proper evidence does not exist for each genetic disorder.
In large-scale, prospective studies, it has been shown that physical fitness level and all-cause mortality are inversely related, even when corrected for other known risk factors. VO2peak reflects the physiological correlate of oxidative capacity in the muscular and cardiovascular systems. Low VO2peak is linked with an increased risk of ischemic heart disease, cancer and metabolic syndrome.
As a result, increasing VO2peak in patients with cardiomyopathy, who often have low baseline values of VO2peak, could lead to substantial long-term health benefits.
The study is an open label, non-randomized clinical crossover trial, investigating the effect of an 8-week exercise program in patients with pathogenic TTN variants that dispose or has resulted in cardiomyopathy.
The crossover trial has a two-period design. In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health. In the second period, participants will perform regular moderate-intensity exercise 3 times/week. Both study periods will last 8 weeks.
Based on results from prior trials we estimated that training would improve VO2peak by 10% (an estimated absolute increase of 2.5 ml O2/kg/min) with a standard deviation of 8.5%. Accordingly, we estimated that inclusion of 10 subjects would provide a power of 91% to detect this difference at a significance level of 0.05, using a paired t-test. Assuming a drop-out-rate of 20% a total of 14 patients should as a minimum be enrolled in the study. As a result, we aimed for the inclusion of a minimum of 14 trial participants, but up to 27 (if practically feasible) to make the evaluation of underlying physiological mechanisms leading to improved fitness possible.
Our hypothesis is that moderate-intensity exercise training safely improves oxidative capacity and that beneficial effects are partly caused by improvements in cardiac contractility.
In vitro experiments on human induced pluripotent stem cells show that TTNtv leads to sarcomere insufficiency, impaired responses to mechanical and β-adrenergic stress, and attenuated growth factor and cell signaling activation. Experiments in animal models suggest patients with TTNtv are intolerant to long-lasting hemodynamic stress. This finding is supported by clinical studies in which a significant proportion of patients with peripartum cardiomyopathy, alcoholic cardiomyopathy and chemotherapy-induced cardiomyopathy were found to carry TTNtv.
So far, no interventional studies have been carried out specifically in patients with TTNtv. In an older study putative variants in TTN have been suggested to be associated with cardiac adaptations to endurance training, namely the rate of change in stroke volume during submaximal exercise.
Previous interventional exercise-studies in patients with a range of mutations in genes encoding proteins of the cytoskeleton, sarcomere, ion-channels and enzymes of the mitochondrial respiratory chain, safely improves oxidative fitness. Studies carried out on patients with heart failure of mixed etiologies and in patients with hypertrophic cardiomyopathy reveals similar beneficial effects of exercise. These studies reject the idea that training "diseased" muscle tissue leads to further muscle damage or is ineffective.
Many patients with cardiomyopathy often lead a sedentary life but aspire to live a physically active lifestyle and take advantage of the many documented health benefits of exercise. However, recommendations for engaging in physical activity in patients with heart failure and cardiomyopathies are vague since proper evidence does not exist for each genetic disorder.
In large-scale, prospective studies, it has been shown that physical fitness level and all-cause mortality are inversely related, even when corrected for other known risk factors. VO2peak reflects the physiological correlate of oxidative capacity in the muscular and cardiovascular systems. Low VO2peak is linked with an increased risk of ischemic heart disease, cancer and metabolic syndrome.
As a result, increasing VO2peak in patients with cardiomyopathy, who often have low baseline values of VO2peak, could lead to substantial long-term health benefits.
The study is an open label, non-randomized clinical crossover trial, investigating the effect of an 8-week exercise program in patients with pathogenic TTN variants that dispose or has resulted in cardiomyopathy.
The crossover trial has a two-period design. In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health. In the second period, participants will perform regular moderate-intensity exercise 3 times/week. Both study periods will last 8 weeks.
Based on results from prior trials we estimated that training would improve VO2peak by 10% (an estimated absolute increase of 2.5 ml O2/kg/min) with a standard deviation of 8.5%. Accordingly, we estimated that inclusion of 10 subjects would provide a power of 91% to detect this difference at a significance level of 0.05, using a paired t-test. Assuming a drop-out-rate of 20% a total of 14 patients should as a minimum be enrolled in the study. As a result, we aimed for the inclusion of a minimum of 14 trial participants, but up to 27 (if practically feasible) to make the evaluation of underlying physiological mechanisms leading to improved fitness possible.
Our hypothesis is that moderate-intensity exercise training safely improves oxidative capacity and that beneficial effects are partly caused by improvements in cardiac contractility.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cardiomyopathies
Truncation Mutation
TTN
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
CROSSOVER
The crossover trial has a two-period design. In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health. In the second period, participants will perform regular moderate-intensity exercise 3 times/week. Both study periods will last 8 weeks.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo periode
In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Exercise periode
In the second period, participants will perform regular moderate-intensity exercise 3 times/week.
Group Type
EXPERIMENTAL
Training
Intervention Type
BEHAVIORAL
In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Training
In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥ 18 years
2. Mutations in the TTN gene leading to truncating variants in cardiac expressed exons of titin.
3. A clinical diagnosis of dilated cardiomyopathy or fulfulling criteria for the diagnosis of heart failure or hypokinetic non-dilated cardiomyopathy.
2. Mutations in the TTN gene leading to truncating variants in cardiac expressed exons of titin.
3. A clinical diagnosis of dilated cardiomyopathy or fulfulling criteria for the diagnosis of heart failure or hypokinetic non-dilated cardiomyopathy.
Exclusion Criteria
1. New York Heart Association functional class IV.
2. Patients with a left ventricular assist device or who have had a heart transplant.
3. Change in heart failure medications within the last month.
4. CRT implantation within the last 6 months.
5. Inability to perform exercise due to orthopedic or other non-cardiovascular limitations.
6. Clinical history of exercise-induced syncope likely caused by ventricular tachyarrhythmias.
7. Current participation in moderate or high intensity exercise exceeding 2.5 hours/per week.
8. Inability to give informed consent.
9. Pregnant women.
10. Severe vascular disease (IE claudicatio intermittens).
11. Severe valvular disease (moderate aortic stenosis/regurgitation or severe mitral regurgitation/stenosis).
12. Life expectancy less than 12 months.
13. Expected reduced compliance.
2. Patients with a left ventricular assist device or who have had a heart transplant.
3. Change in heart failure medications within the last month.
4. CRT implantation within the last 6 months.
5. Inability to perform exercise due to orthopedic or other non-cardiovascular limitations.
6. Clinical history of exercise-induced syncope likely caused by ventricular tachyarrhythmias.
7. Current participation in moderate or high intensity exercise exceeding 2.5 hours/per week.
8. Inability to give informed consent.
9. Pregnant women.
10. Severe vascular disease (IE claudicatio intermittens).
11. Severe valvular disease (moderate aortic stenosis/regurgitation or severe mitral regurgitation/stenosis).
12. Life expectancy less than 12 months.
13. Expected reduced compliance.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ida Finsen Flensted
Bach.med.
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Vissing, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 Feb 16;366(7):619-28. doi: 10.1056/NEJMoa1110186.
Reference Type
BACKGROUND
Tayal U, Prasad S, Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med. 2017 Feb 22;9(1):20. doi: 10.1186/s13073-017-0410-8.
Reference Type
BACKGROUND
Ahlberg G, Refsgaard L, Lundegaard PR, Andreasen L, Ranthe MF, Linscheid N, Nielsen JB, Melbye M, Haunso S, Sajadieh A, Camp L, Olesen SP, Rasmussen S, Lundby A, Ellinor PT, Holst AG, Svendsen JH, Olesen MS. Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation. Nat Commun. 2018 Oct 17;9(1):4316. doi: 10.1038/s41467-018-06618-y.
Reference Type
BACKGROUND
Corden B, Jarman J, Whiffin N, Tayal U, Buchan R, Sehmi J, Harper A, Midwinter W, Lascelles K, Markides V, Mason M, Baksi J, Pantazis A, Pennell DJ, Barton PJ, Prasad SK, Wong T, Cook SA, Ware JS. Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators. JAMA Netw Open. 2019 Jun 5;2(6):e196520. doi: 10.1001/jamanetworkopen.2019.6520.
Reference Type
BACKGROUND
Tayal U, Newsome S, Buchan R, Whiffin N, Walsh R, Barton PJ, Ware JS, Cook SA, Prasad SK. Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy. J Am Coll Cardiol. 2017 May 16;69(19):2466-2468. doi: 10.1016/j.jacc.2017.03.530. No abstract available.
Reference Type
BACKGROUND
Choi SH, Weng LC, Roselli C, Lin H, Haggerty CM, Shoemaker MB, Barnard J, Arking DE, Chasman DI, Albert CM, Chaffin M, Tucker NR, Smith JD, Gupta N, Gabriel S, Margolin L, Shea MA, Shaffer CM, Yoneda ZT, Boerwinkle E, Smith NL, Silverman EK, Redline S, Vasan RS, Burchard EG, Gogarten SM, Laurie C, Blackwell TW, Abecasis G, Carey DJ, Fornwalt BK, Smelser DT, Baras A, Dewey FE, Jaquish CE, Papanicolaou GJ, Sotoodehnia N, Van Wagoner DR, Psaty BM, Kathiresan S, Darbar D, Alonso A, Heckbert SR, Chung MK, Roden DM, Benjamin EJ, Murray MF, Lunetta KL, Lubitz SA, Ellinor PT; DiscovEHR study and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA. 2018 Dec 11;320(22):2354-2364. doi: 10.1001/jama.2018.18179.
Reference Type
BACKGROUND
Verdonschot JAJ, Hazebroek MR, Derks KWJ, Barandiaran Aizpurua A, Merken JJ, Wang P, Bierau J, van den Wijngaard A, Schalla SM, Abdul Hamid MA, van Bilsen M, van Empel VPM, Knackstedt C, Brunner-La Rocca HP, Brunner HG, Krapels IPC, Heymans SRB. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J. 2018 Mar 7;39(10):864-873. doi: 10.1093/eurheartj/ehx808.
Reference Type
BACKGROUND
Roberts AM, Ware JS, Herman DS, Schafer S, Baksi J, Bick AG, Buchan RJ, Walsh R, John S, Wilkinson S, Mazzarotto F, Felkin LE, Gong S, MacArthur JA, Cunningham F, Flannick J, Gabriel SB, Altshuler DM, Macdonald PS, Heinig M, Keogh AM, Hayward CS, Banner NR, Pennell DJ, O'Regan DP, San TR, de Marvao A, Dawes TJ, Gulati A, Birks EJ, Yacoub MH, Radke M, Gotthardt M, Wilson JG, O'Donnell CJ, Prasad SK, Barton PJ, Fatkin D, Hubner N, Seidman JG, Seidman CE, Cook SA. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015 Jan 14;7(270):270ra6. doi: 10.1126/scitranslmed.3010134.
Reference Type
BACKGROUND
Jansweijer JA, Nieuwhof K, Russo F, Hoorntje ET, Jongbloed JD, Lekanne Deprez RH, Postma AV, Bronk M, van Rijsingen IA, de Haij S, Biagini E, van Haelst PL, van Wijngaarden J, van den Berg MP, Wilde AA, Mannens MM, de Boer RA, van Spaendonck-Zwarts KY, van Tintelen JP, Pinto YM. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail. 2017 Apr;19(4):512-521. doi: 10.1002/ejhf.673. Epub 2016 Nov 3.
Reference Type
BACKGROUND
Jansen M, Baas AF, van Spaendonck-Zwarts KY, Ummels AS, van den Wijngaard A, Jongbloed JDH, van Slegtenhorst MA, Lekanne Deprez RH, Wessels MW, Michels M, Houweling AC, Hoorntje ET, Helderman-van den Enden PJTM, Barge-Schaapveld DQCM, Peter van Tintelen J, van den Berg MP, Wilde AAM, Ploos van Amstel HK, Hennekam EAM, Asselbergs FW, Sijbrands EJG, Dooijes D. Mortality Risk Associated With Truncating Founder Mutations in Titin. Circ Genom Precis Med. 2019 May;12(5):e002436. doi: 10.1161/CIRCGEN.118.002436.
Reference Type
BACKGROUND
Verdonschot JAJ, Hazebroek MR, Wang P, Sanders-van Wijk S, Merken JJ, Adriaansen YA, van den Wijngaard A, Krapels IPC, Brunner-La Rocca HP, Brunner HG, Heymans SRB. Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy. Circ Heart Fail. 2018 Nov;11(11):e005220. doi: 10.1161/CIRCHEARTFAILURE.118.005220.
Reference Type
BACKGROUND
Felkin LE, Walsh R, Ware JS, Yacoub MH, Birks EJ, Barton PJ, Cook SA. Recovery of Cardiac Function in Cardiomyopathy Caused by Titin Truncation. JAMA Cardiol. 2016 May 1;1(2):234-5. doi: 10.1001/jamacardio.2016.0208. No abstract available.
Reference Type
BACKGROUND
Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, Gorham J, Yang L, Schafer S, Sheng CC, Haghighi A, Homsy J, Hubner N, Church G, Cook SA, Linke WA, Chen CS, Seidman JG, Seidman CE. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015 Aug 28;349(6251):982-6. doi: 10.1126/science.aaa5458.
Reference Type
BACKGROUND
Huttner IG, Wang LW, Santiago CF, Horvat C, Johnson R, Cheng D, von Frieling-Salewsky M, Hillcoat K, Bemand TJ, Trivedi G, Braet F, Hesselson D, Alford K, Hayward CS, Seidman JG, Seidman CE, Feneley MP, Linke WA, Fatkin D. A-Band Titin Truncation in Zebrafish Causes Dilated Cardiomyopathy and Hemodynamic Stress Intolerance. Circ Genom Precis Med. 2018 Aug;11(8):e002135. doi: 10.1161/CIRCGEN.118.002135.
Reference Type
BACKGROUND
Gramlich M, Michely B, Krohne C, Heuser A, Erdmann B, Klaassen S, Hudson B, Magarin M, Kirchner F, Todiras M, Granzier H, Labeit S, Thierfelder L, Gerull B. Stress-induced dilated cardiomyopathy in a knock-in mouse model mimicking human titin-based disease. J Mol Cell Cardiol. 2009 Sep;47(3):352-8. doi: 10.1016/j.yjmcc.2009.04.014. Epub 2009 May 4.
Reference Type
BACKGROUND
Zhou Q, Kesteven S, Wu J, Aidery P, Gawaz M, Gramlich M, Feneley MP, Harvey RP. Pressure Overload by Transverse Aortic Constriction Induces Maladaptive Hypertrophy in a Titin-Truncated Mouse Model. Biomed Res Int. 2015;2015:163564. doi: 10.1155/2015/163564. Epub 2015 Oct 4.
Reference Type
BACKGROUND
Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J 3rd, McNamara DM, Seidman CE, Seidman JG, Arany Z; IMAC-2 and IPAC Investigators. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016 Jan 21;374(3):233-41. doi: 10.1056/NEJMoa1505517. Epub 2016 Jan 6.
Reference Type
BACKGROUND
Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchia J, Garcia-Pinilla JM, Pascual-Figal DA, Nunez J, Guzzo-Merello G, Gonzalez-Vioque E, Bardaji A, Manito N, Lopez-Garrido MA, Padron-Barthe L, Edwards E, Whiffin N, Walsh R, Buchan RJ, Midwinter W, Wilk A, Prasad S, Pantazis A, Baski J, O'Regan DP, Alonso-Pulpon L, Cook SA, Lara-Pezzi E, Barton PJ, Garcia-Pavia P. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018 May 22;71(20):2293-2302. doi: 10.1016/j.jacc.2018.03.462.
Reference Type
BACKGROUND
Linschoten M, Teske AJ, Baas AF, Vink A, Dooijes D, Baars HF, Asselbergs FW. Truncating Titin (TTN) Variants in Chemotherapy-Induced Cardiomyopathy. J Card Fail. 2017 Jun;23(6):476-479. doi: 10.1016/j.cardfail.2017.03.003. Epub 2017 Mar 14.
Reference Type
BACKGROUND
Rankinen T, Rice T, Boudreau A, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C. Titin is a candidate gene for stroke volume response to endurance training: the HERITAGE Family Study. Physiol Genomics. 2003 Sep 29;15(1):27-33. doi: 10.1152/physiolgenomics.00147.2002.
Reference Type
BACKGROUND
Sveen ML, Jeppesen TD, Hauerslev S, Kober L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain. 2008 Nov;131(Pt 11):2824-31. doi: 10.1093/brain/awn189. Epub 2008 Sep 6.
Reference Type
BACKGROUND
Jeppesen TD, Duno M, Schwartz M, Krag T, Rafiq J, Wibrand F, Vissing J. Short- and long-term effects of endurance training in patients with mitochondrial myopathy. Eur J Neurol. 2009 Dec;16(12):1336-9. doi: 10.1111/j.1468-1331.2009.02660.x. Epub 2009 May 27.
Reference Type
BACKGROUND
Sveen ML, Jeppesen TD, Hauerslev S, Krag TO, Vissing J. Endurance training: an effective and safe treatment for patients with LGMD2I. Neurology. 2007 Jan 2;68(1):59-61. doi: 10.1212/01.wnl.0000250358.32199.24.
Reference Type
BACKGROUND
Vissing CR, Preisler N, Husu E, Prahm KP, Vissing J. Aerobic training in patients with anoctamin 5 myopathy and hyperckemia. Muscle Nerve. 2014 Jul;50(1):119-23. doi: 10.1002/mus.24112. Epub 2014 May 5.
Reference Type
BACKGROUND
Andersen G, Heje K, Buch AE, Vissing J. High-intensity interval training in facioscapulohumeral muscular dystrophy type 1: a randomized clinical trial. J Neurol. 2017 Jun;264(6):1099-1106. doi: 10.1007/s00415-017-8497-9. Epub 2017 May 3.
Reference Type
BACKGROUND
Orngreen MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type 1. Ann Neurol. 2005 May;57(5):754-7. doi: 10.1002/ana.20460.
Reference Type
BACKGROUND
O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pina IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009 Apr 8;301(14):1439-50. doi: 10.1001/jama.2009.454.
Reference Type
BACKGROUND
Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A, Concannon M, Dries AM, Shmargad Y, Salisbury H, Kumar S, Herrera JJ, Myers J, Helms AS, Ashley EA, Day SM. Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA. 2017 Apr 4;317(13):1349-1357. doi: 10.1001/jama.2017.2503.
Reference Type
BACKGROUND
Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, Deal BJ, Driscoll DJ, Estes NA 3rd, Araujo CG, Liang DH, Mitten MJ, Myerburg RJ, Pelliccia A, Thompson PD, Towbin JA, Van Camp SP; Working Groups of the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention; Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004 Jun 8;109(22):2807-16. doi: 10.1161/01.CIR.0000128363.85581.E1.
Reference Type
BACKGROUND
Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA. 1989 Nov 3;262(17):2395-401. doi: 10.1001/jama.262.17.2395.
Reference Type
BACKGROUND
Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011 Aug 16;124(7):789-95. doi: 10.1161/CIRCULATIONAHA.110.010710. Epub 2011 Aug 1.
Reference Type
BACKGROUND
Laukkanen JA, Zaccardi F, Khan H, Kurl S, Jae SY, Rauramaa R. Long-term Change in Cardiorespiratory Fitness and All-Cause Mortality: A Population-Based Follow-up Study. Mayo Clin Proc. 2016 Sep;91(9):1183-8. doi: 10.1016/j.mayocp.2016.05.014. Epub 2016 Jul 18.
Reference Type
BACKGROUND
Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med. 1988 Nov 24;319(21):1379-84. doi: 10.1056/NEJM198811243192104.
Reference Type
BACKGROUND
Paffenbarger RS Jr, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med. 1993 Feb 25;328(8):538-45. doi: 10.1056/NEJM199302253280804.
Reference Type
BACKGROUND
Flensted IF, Stemmerik MG, Skriver SV, Axelsen KH, Christensen AH, Lundby C, Bundgaard H, Vissing J, Vissing CR. Exercise training improves cardiovascular fitness in dilated cardiomyopathy caused by truncating titin variants. Heart. 2024 Nov 25;110(24):1416-1425. doi: 10.1136/heartjnl-2024-323995.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
75682
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
NCT00275145
COMPLETED
PHASE2
Impact of Exercise Training on Cardiac Function in Man
NCT01881139
COMPLETED
EARLY_PHASE1
Resistance and/or Endurance Training, What is Most Effective in Prevention of Cardiovascular Diseases?
NCT00986024
COMPLETED
NA
Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women
NCT00000108
COMPLETED
NA
Effect of Aerobic Exercise Training in Obese Adults
NCT05202535
COMPLETED
NA
Acute Responses to Exercise in Females and Males With Symptomatic Atrial Fibrillation
NCT05085860
RECRUITING
NA
Influence of Cardiorespiratory Fitness and Body Composition on Resting and Post-exercise Indices of Vascular Health in Young Adults
NCT06163456
COMPLETED
NA
Impact of Exercise Training Intensity on Abdominal Visceral Fat and Risk Factors Associated With the Metabolic Syndrome
NCT00350064
UNKNOWN
NA
Aerobic Interval and Moderate Continuous Exercise Training on Ventricular Functions
NCT04815460
COMPLETED
NA
Effect of Exercise on Heart Function in Healthy Elderly People
NCT00804518
COMPLETED
NA
Individual Variability to Aerobic Exercise Training
NCT02868710
COMPLETED
NA
Genetic Polymorphisms Affecting Effect of High Intensity Training
NCT02241850
COMPLETED
NA
Effect of 3 Years of Exercise in Patients With Atrial Fibrillation
NCT01673139
COMPLETED
NA
Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19
NCT04549337
COMPLETED
NA
Optimal Exercise Regimens for Persons at Increased Risk
NCT00000523
COMPLETED
PHASE2
Resistance Training and Cardiometabolic Health
NCT03325933
TERMINATED
NA
Effect of Training in Normobaric Hypoxia on Cardiac Markers
NCT06896773
ENROLLING_BY_INVITATION
NA
Gerofit Exercise Intervention for Older Adults With Sickle Cell Disease (SICKLE-FIT Study)
NCT05714098
COMPLETED
NA
Effect of Concurrent and Aerobic Exercise on VO2max, Strength, and Body Composition in Overweight and Obese Adults
NCT05867498
COMPLETED
NA
The Effects of High-Intensity Exercise on Biological Age
NCT05156918
COMPLETED
NA
Physical Exercise and Coronary Artery Plaque Composition
NCT01228201
COMPLETED
NA
Acute Effect of Individual Variants of Agonist-antagonist and Traditional Agonistic Resistance Training on Cardiovascular Parameters
NCT06047678
ACTIVE_NOT_RECRUITING
NA
Sequelae of COVID-19 With Focus on Exercise Capacity and Underlying Mechanisms
NCT05118711
UNKNOWN
Oxygen Transport in Normobaric vs. Hypobaric Hypoxia
NCT03335917
COMPLETED
NA
Resistance Training in Adults With Obesity
NCT05092061
COMPLETED
NA